Disclosed are Nogo receptor proteins and biologically active Nogo (ligand) protein
fragments. Also disclosed are com positions and methods for modulating the expression or …

Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also
disclosed are compositions and methods for modulating the expression or activity of the …

Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also
disclosed are compositions and methods for modulating the expression or activity of the …

Related US Application Data 514/12: 435/7.21 (60) Division of application No. 09/972,599,
filed on Oct. 6, 2001, now Pat. No. 7,119,165, which is a continua-(57) ABSTRACT sing RS …

0002 Functional recovery following injury to the central nervous system (CNS) of adult
higher vertebrates is excep tionally limited, resulting in persistent neurological deficits Such …

the present invention relates to methods and compositions for treating or ameliorating spinal
cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke …

514/45 (57) ABSTRACT The present invention is based on the discovery that Suppress ing
the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration …

2010-03-19 Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), US DEPT. OF HEALTH
AND HUMAN SERVICES (DHHS), US GOVERNMENT reassignment NATIONAL …

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies,
antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and …

The invention provides methods for treating diseases involving aberrant amyloid-β (Aβ)
peptide deposition, including Alzheimer's Disease, by the administration of Nogo receptor …